Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes

Ryotaro Bouchi1 · Tatsuya Fukuda1 · Takato Takeuchi1 · Yujiro Nakano1 · Masanori Murakami1 · Isao Minami1 · Hajime Izumiyama1,2 · Koshi Hashimoto1,3 · Takanobu Yoshimoto1 · Yoshihiro Ogawa1,4

Received: 20 November 2016 / Accepted: 1 February 2017 / Published online: 28 February 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract  Sarcopenia is defined as an age-related loss of skeletal muscle mass and strength, and is a major cause of disability and mobility limitations. Recent studies have demonstrated that type 2 diabetes and insulin signaling deficiencies contribute to the progression of sarcopenia, suggesting that a sufficient supply of insulin to the skeletal muscles may be important for the maintenance of muscle function; however, little has been reported regarding whether insulin treatment can protect against sarcopenia. We conducted a retrospective observational study to examine the impact of insulin treatment on the muscle mass of patients with type 2 diabetes. A total of 312 patients (mean age: 64 ± 11 years; 40.8% female; 27.6% treated with insulin) were studied in this retrospective observational study. Skeletal muscle index (SMI) and grip strength (kg) were used to assess sarcopenia. The prevalence of sarcopenia was 18.0%. Insulin treatment was shown to be protective against the annual decline of SMI (standardized β 0.195; p = 0.025) even after adjusting for covariates, including age, gender, duration of diabetes, and body mass index. In a cohort matched by propensity scores, insulin treatment significantly increased the 1-year change in SMI (mean ± SE) compared with non-insulin-treated group (2.40 ± 0.98% vs. −0.43 ± 0.98%; p = 0.050). Our data suggest that insulin treatment could attenuate the progression of sarcopenia in patients with type 2 diabetes.

Keywords  Sarcopenia · Insulin · Type 2 diabetes · Diabetes treatment
Introduction

Sarcopenia is defined as the loss of skeletal muscle mass and strength that occurs with aging and is a major cause of disability and mobility limitations [1–3]. Although it has been clearly shown that sarcopenia has an adverse effect on mobility, the quality of life (QOL), and mortality [2, 4], the diagnostic thresholds of muscle mass and strength remain controversial. In 2010, the European Working Group on Sarcopenia in Older People was the first to achieve a consensus on the definition of sarcopenia, including the diagnostic thresholds for muscle mass and strength [1]. Subsequently, similar definitions were created by the International Working Group on Sarcopenia [2] and Asian Working Group for Sarcopenia (the criteria for Asian population) [3]. However, these definitions were determined based on the results of various studies using individual definitions of sarcopenia and diagnostic thresholds in each study. In addition, it remains uncertain whether the consensus made much such groups is applicable to patients of any race or those with chronic diseases. Of the chronic diseases, diabetes has been reported to be one of the significant contributors to the exacerbation of sarcopenia [5–8]. The Health, Aging, and Body Composition Study revealed that elderly patients with diabetes have lower muscle strength than non-diabetic subjects [6]. Using a longitudinal survey, this research group also reported that patients with diabetes have an increased risk for the excessive loss of both skeletal muscle mass and strength, particularly in the lower extremities [7, 8]. Given these findings, patients with diabetes are thought to be susceptible to mobility-related disabilities through the loss of muscle mass and strength primarily in the lower extremities.

Resistance training with protein supplementation was reported to be the most effective form of treatment for sarcopenia, [9, 10]. Pharmaceutical therapies have also been studied; however, there is insufficient evidence supporting effective medication for the treatment of sarcopenia [11]. In diabetic patients, poor glycemic control and insulin resistance are independently associated with the decline of skeletal muscle mass among elderly patients with diabetes [12, 13]. Consequently, these abnormalities could be considered a therapeutic target for sarcopenia. Indeed, it was reported that insulin sensitizers may attenuate the decline in muscle mass in patients with diabetes [14]. In addition, low endogenous insulin secretion was also associated with muscle mass among patients with diabetes [15]. Furthermore, supraphysiological hyperinsulinemia has been reported to be necessary for the stimulation of muscle protein synthesis and anabolic signaling in elderly subjects [16], suggesting that sufficient insulin supply could provide protection against the progression of sarcopenia in patients with diabetes. Therefore, we investigated the impact of insulin treatment on sarcopenia in patients with type 2 diabetes.

Methods

Subjects

We screened type 2 diabetic patients aged older than 20 years who regularly visited the Tokyo Medical and Dental University Hospital for at least 1 year and had undergone a whole-body dual-energy X-ray absorptiometry (DXA) from July 1, 2012 to December 31, 2015. As shown in Figs. 1, 2, 374 patients aged more than 20 years at our hospital had undergone a whole-body DXA during the study period, of whom 1305 patients were diagnosed as having type 2 diabetes. We selected 352 patients with type 2 diabetes who had undergone a second DXA measurement with an elapsed time greater than 9 months to evaluate body composition. Exclusion criteria included severe liver disease, renal impairment (estimated glomerular filtration rate (GFR) [eGFR] < 15 mL/min/1.73 m² or undergoing renal replacement therapy), pregnancy, infectious diseases, and cancer. Finally, 312 patients were enrolled in this retrospective study (Fig. 1). The median with interquartile range of the period between the first and second DXA measurement was 1.04 years (0.94–1.42 years). The patients were divided

| Subjects with DXA from July 1, 2012 to December 31, 2015 (N = 2374) |
|------------------------|
| Patients with type 2 diabetes (N = 1305) |
| Second measurement of DXA with an elapsed time of at least 9 months (N = 352) |
| Met exclusion criteria (N = 40) |
| Final study sample after exclusion (N = 312) |

Fig. 1 Flow chart
into an insulin-treated group (N = 86) and non-insulin-treated group (N = 216). The present study complied with the Declaration of Helsinki and was approved by the research ethics committee of Tokyo Medical and Dental University.

Measurement of Body Composition

To evaluate the SMI, fat and fat-free tissue mass were measured using whole-body DXA (Lunar iDXA, GE Healthcare, Madison, WI). The patients were positioned for whole-body scans in accordance with the manufacturer’s protocol. The whole-body fat-free mass was divided into several regions (e.g., arms, legs, and trunk). Appendicular muscle mass was estimated as the sum of the fat-free mass of both the upper and lower limbs. The SMI was calculated as the appendicular muscle mass divided by the square of the height (kg/m²). Grip strength (kg) was measured using the hand dynamometer Grip-D (TKK5401, Takei, Niigata, Japan). The average grip strength was used for muscle strength. According to the Asian sarcopenia criteria [3], an SMI <7.0 in males and <5.4 in females, as well as a grip strength <26.0 kg in males and <18.0 kg in females were defined as low muscle mass and reduced grip strength, respectively. Eventually, the patients with both low muscle mass and reduced grip strength were diagnosed with sarcopenia. The annual changes in SMI, and the muscle mass in the upper and lower extremities (%/year) were also determined.

Clinical and Biochemical Analysis

Information was obtained from the patients’ medical records regarding the medications for diabetes, dyslipidemia, hypertension, hyperuricemia, and anti-platelet agents, duration of diabetes, diabetic retinopathy, history of cardiovascular disease (CVD), and smoking status. CVD was defined as the presence of a previous stroke, myocardial infarction, or coronary revascularization procedure. Smoking history was classified as either current or non-smokers. The systolic and diastolic blood pressures (SBP and DBP) were measured in a sitting position after at least 5 min rest, using an electronic sphygmomanometer (ESH55, Terumo Inc., Tokyo, Japan). The BMI was calculated as the weight divided by the square of the height (kg/m²). Routine tests included alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (γ-GTP), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, and uric acid. All tests were determined using standard laboratory procedures. The triglycerides-to-HDL cholesterol (TG/HDL-C) ratio was used for the assessment of insulin resistance. HbA1c was measured using the latex agglutination method. Urinary albumin and creatinine excretion were measured in a spot urine collection by a turbidimetric immunoassay and enzymatic method. The ratio (ACR, mg/g) was used for the assessment of albuminuria. The GFR, ml/min/1.73 m² was calculated using the equation for Japanese [17].

Statistical Analysis

Statistical analysis was carried out using IBM SPSS version 21.0 (IBM, Armonk, NY, USA), and the results were expressed as the mean ± SD, median, and interquartile range or percentages. A T-test, Mann–Whitney U test, or Chi-square test as appropriate were used for group comparisons (with insulin vs. without insulin). Linear regression analyses with a stepwise procedure were used to assess the factors associated with a 1-year change in SMI. The examined putative risk factors consisted of the duration of diabetes, smoking status, history of CVD, grip strength, BMI, SBP, TG/HDL-C ratio, HbA1c, eGFR, as well as the use of insulin, oral hypoglycemic agents, angiotensin receptor blockers, and statins (multivariate model 1). Age and gender were forced into the models because these are strong determinants of muscle mass and function. We also determined the 1-year changes in HbA1c, BMI, and other markers.
for cardiometabolic risks, including lipid and uric acid levels. We also examined the correlation for the change in SMI with the changes in these parameters (Pearson correlation). We then created a multivariate regression model (multivariate model 2) in which the covariates that were significantly correlated with a change in SMI and the covariates selected in the multivariate model 1 were entered. Finally, we performed propensity score (PS) matching to eliminate any possible treatment bias. The PS was calculated using multivariable logistic regression models that included the following parameters: age, gender, BMI, HbA1c, and duration of diabetes, logarithmically transformed urinary ACR, and eGFR. For the calculation of the PS, the dependent variable was insulin treatment at baseline. We performed 1:1 matching on the PS using nearest neighbor matching with a maximum caliber of 0.01 of the PS. The annual change in SMI (mean ± SE) was compared between the insulin-treated and non-insulin-treated patients using analysis of covariance (ANCOVA). The differences were considered to be statistically significant at a p-value less than 0.05.

### Results

A total of 312 Japanese patients with type 2 diabetes (mean age: 64 ± 11 years; 40.8% female; range: 21–89 years old) were studied. Table 1 presents the clinical characteristics of the study participants. The insulin-treated patients exhibited significantly higher levels of SBP and urinary ACR, a longer duration of diabetes, higher prevalence of diabetic retinopathy, and lower levels of grip strength, triglycerides, AST, ALT, and eGFR than the non-insulin-treated patients. As shown in Table 2, the insulin-treated patients were significantly more likely to receive diuretics and calcium channel blockers, but less likely to receive sulfonylureas and dipeptidyl peptidase-4 (DPP4) inhibitors than the non-insulin-treated patients.

As shown in Table 3, insulin treatment was found to be protective against the annual decline of SMI in the univariate and gender- and age-adjusted models. In the multivariate model, which includes the duration of diabetes and BMI in addition to age and gender as covariates (multivariate model 1), the patients with treated with insulin were at a significantly lower risk for the decline of SMI than those who did not receive insulin treatment. In addition, insulin

| **Table 1** Clinical characteristics in patients with type 2 diabetes |
|-----------------|-----------------|-----------------|**p-values**|
| **Age (years)** | 63 ± 12 | 66 ± 12 | 0.031 |
| **Gender (% female)** | 38 | 42 | 0.610 |
| **Systolic blood pressure (mmHg)** | 126 ± 15 | 130 ± 16 | 0.031 |
| **Diastolic blood pressure (mmHg)** | 75 ± 13 | 75 ± 15 | 0.774 |
| **Body mass index (kg/m²)** | 25.1 ± 4.6 | 24.3 ± 3.8 | 0.172 |
| **Grip strength (kg)** | 29.4 (20.3–36.5) | 22.9 (17.2–30.3) | 0.001 |
| **Skeletal muscle index** | 6.7 (5.9–7.6) | 6.4 (5.8–7.2) | 0.263 |
| **Body fat (%)** | 33.6 ± 7.1 | 34.3 ± 8.5 | 0.549 |
| **Duration of diabetes (years)** | 6 (3–9) | 10 (3–18) | <0.001 |
| **Proliferative diabetic retinopathy (%)** | 2 | 17 | <0.001 |
| **Previous cardiovascular disease (%)** | 11 | 9 | 0.729 |
| **Current smoking (%)** | 11 | 13 | 0.501 |
| **HbA1c (mmol/mol)** | 51.7 ± 15.4 | 61.9 ± 15.4 | <0.001 |
| **HbA1c (%)** | 6.9 ± 1.4 | 7.8 ± 1.4 | 0.034 |
| **TG (mmol/l)** | 1.37 (1.02–2.35) | 1.15 (0.89–2.02) | 1.03 |
| **HDL cholesterol (mmol/l)** | 1.49 ± 0.42 | 1.58 ± 0.45 | 0.133 |
| **TG/HDL cholesterol ratio** | 2.15 (1.39–3.95) | 1.91 (1.13–3.78) | 0.271 |
| **LDL cholesterol (mmol/l)** | 2.82 (2.41–3.34) | 2.84 (2.22–3.49) | 0.416 |
| **AST (U/l)** | 23 (21–32) | 21 (19–25) | 0.004 |
| **ALT (U/l)** | 23 (17–35) | 18 (15–27) | 0.001 |
| **γ-GTP (U/l)** | 35 (22–62) | 31 (20–46) | 0.051 |
| **Uric acid (μmol/l)** | 312 (274–364) | 312 (262–372) | 0.648 |
| **Albumin-to-creatinine ratio (mg/g)** | 22 (14–59) | 32 (14–133) | 0.042 |
| **eGFR (ml/min/1.73 m²)** | 75.5 ± 19.7 | 69.6 ± 27.6 | 0.035 |

*ALT* alanine transaminase, *AST* aspartate transaminase, *eGFR* estimated glomerular filtration ratio, *GTP* glutamyl transpeptidase, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *TG* triglycerides
Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes

Treatment was significantly and positively associated with the annual change in the muscle mass of the lower extremities (standardized β 0.213; p = 0.015) but not with that of the upper extremities (standardized β −0.012; p = 0.892) in the multivariate models. Since the 1-year change in SMI was significantly correlated with the BMI (r = 0.279; p < 0.001) and HbA1c (r = −0.162; p = 0.043) levels, we constructed a multivariate model in which the changes in BMI and HbA1c were added as covariates (multivariate model 2). In the model, insulin treatment was shown to be protective against a decline in SMI with a statistical significance. Insulin treatment was significantly associated with SMI in the lower but not the upper extremities in the multivariate models. Other significant covariates included in the model were the duration of diabetes and BMI at baseline. Although grip strength was strongly correlated with SMI (r = 0.637; p < 0.001) and SMI in the upper (r = 0.733; p < 0.001) and lower (r = 0.570; p < 0.001) extremities at baseline, grip strength was not correlated with the change in SMI (r = −0.032; p = 0.674) and SMI in the upper (r = 0.031; p = 0.680) and lower (r = −0.050, p = 0.509) extremities. Finally, grip strength was not selected in the multivariate models.

In a propensity-matched cohort (Fig. 2), insulin treatment significantly increased the SMI in 1-year (mean ± SE) compared with the non-insulin-treated group (2.40 ± 0.98%)

### Table 2 Medications for patients with type 2 diabetes

| Medication        | Insulin (−) (N = 216) | Insulin (+) (N = 86) | p-values |
|-------------------|------------------------|----------------------|----------|
| Sulfonylureas (%) | 18                     | 4                    | 0.002    |
| Biguanides (%)    | 25                     | 22                   | 0.662    |
| Alpha-GIs (%)     | 5                      | 8                    | 0.241    |
| Glinides (%)      | 3                      | 2                    | 0.817    |
| TZDs (%)          | 5                      | 4                    | 0.861    |
| DPP4 inhibitors (%) | 36                    | 22                   | 0.021    |
| GLP1-R agonists (%) | 2                    | 1                    | 0.666    |
| SGLT2 inhibitors (%) | 2                   | 0                    | 0.369    |
| ACEIs (%)         | 4                      | 3                    | 0.775    |
| ARBs (%)          | 33                     | 41                   | 0.153    |
| Calcium channel blockers (%) | 27               | 46                   | 0.001    |
| Beta-blockers (%) | 12                     | 9                    | 0.553    |
| Alpha-blockers (%) | 2                     | 2                    | 0.799    |
| Diuretics (%)     | 7                      | 16                   | 0.014    |
| Statins (%)       | 29                     | 39                   | 0.076    |
| Fibrates (%)      | 2                      | 4                    | 0.289    |
| Ezetimibe (%)     | 5                      | 2                    | 0.280    |
| Uric acid-lowering agents (%) | 7             | 5                    | 0.539    |
| Anti-platelet agents (%) | 11         | 18                   | 0.116    |

ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, DPP4 dipeptidyl peptidase 4, Gls glycosidase inhibitors, GLP1-R glucagon-like peptide 1 receptors, SGLT2 sodium–glucose cotransporter 2, TZDs thiazolidinediones

### Table 3 Factors associated with 1-year change in skeletal muscle mass in patients with type 2 diabetes

|          | SMI | SMI in the upper extremities | SMI in the lower extremities |
|----------|-----|------------------------------|-----------------------------|
|          | Standardized β | p-values | Standardized β | p-values | Standardized β | p-values |
| Univariate | (A-R² = 0.114) | (A-R² = 0.001) | (A-R² = 0.119) |
| Insulin | 0.177 | 0.041 | −0.023 | 0.760 | 0.169 | 0.045 |
| Age- and gender-adjusted | (A-R² = 0.117) | (A-R² = 0.008) | (A-R² = 0.123) |
| Insulin | 0.175 | 0.042 | −0.012 | 0.873 | 0.174 | 0.038 |
| Age | −0.064 | 0.471 | 0.074 | 0.328 | −0.049 | 0.514 |
| Gender | −0.021 | 0.983 | 0.054 | 0.468 | −0.042 | 0.575 |
| Multivariate 1 | (A-R² = 0.165) | (A-R² = 0.008) | (A-R² = 0.197) |
| Insulin | 0.195 | 0.025 | −0.012 | 0.892 | 0.213 | 0.015 |
| Age | −0.139 | 0.132 | 0.074 | 0.328 | −0.071 | 0.387 |
| Gender | 0.024 | 0.771 | 0.054 | 0.468 | −0.030 | 0.682 |
| Duration of diabetes | −0.301 | 0.001 | NS | −0.182 | 0.021 |
| Body mass index | −0.188 | 0.036 | NS | −0.220 | 0.005 |
| Multivariate 2 | (A-R² = 0.177) | (A-R² = 0.018) | (A-R² = 0.215) |
| Insulin | 0.184 | 0.042 | −0.023 | 0.768 | 0.173 | 0.035 |
| Age | −0.062 | 0.554 | −0.035 | 0.664 | −0.024 | 0.782 |
| Gender | 0.007 | 0.933 | 0.061 | 0.427 | −0.018 | 0.810 |
| Duration of diabetes | −0.298 | 0.001 | NS | −0.166 | 0.038 |
| BMI | −0.208 | 0.042 | NS | −0.180 | 0.027 |
| Change in BMI | 0.080 | 0.418 | 0.094 | 0.228 | 0.138 | 0.075 |
| Change in HbA1c | −0.097 | 0.272 | −0.054 | 0.497 | −0.044 | 0.562 |

A-R² adjusted R², BMI body mass index, NS not selected in the model, SMI skeletal muscle index
vs. $-0.43 \pm 0.98\%; p = 0.050$). When the effect of insulin was determined separately for the muscle mass of the upper and lower extremities, insulin significantly attenuated the decline of muscle mass in the lower extremities but not in the upper extremities (Fig. 2).

Finally, we investigated whether the change in SMI in patients treated with insulin could be correlated with body fat (android and gynoid) and cardiometabolic risk factors. The change in SMI was not correlated with that in the android ($r = 0.092; p = 0.247$) and gynoid ($r = 0.031; p = 0.409$). In addition, the change in SMI was significantly correlated with that in HbA1c ($r = -0.150; p = 0.047$), HDL cholesterol ($r = 0.244; p = 0.034$), and uric acid ($r = -0.310; p = 0.009$) but not with triglycerides ($r = -0.068; p = 0.308$), LDL cholesterol ($r = -0.049; p = 0.360$), AST ($r = -0.010; p = 0.471$), ALT ($r = -0.013; p = 0.460$), or gamma GTP ($r = 0.092; p = 0.247$).

**Discussion**

Diabetes is a strong risk factor for the progression of sarcopenia and insulin activity is critical to maintain the balance of muscle protein synthesis and degradation [5]. There is a close association between insulin resistance and sarcopenia. Skeletal muscle is highly responsible for insulin-stimulated glucose uptake which accounts for approximately 75% of the glucose uptake of the entire body. It has been suggested that people with high muscle mass could have increased capacity of glucose uptake and insulin sensitivity in the skeletal muscle and vice versa. In observational and interventional studies [14, 18], insulin sensitizers can increase muscle mass with an improvement in mitochondrial activity and decreased protein degradation in skeletal muscle mass. However, it is uncertain whether insulin treatment could attenuate the loss of skeletal muscle mass and/or function [19, 20]. In addition, the long-term effects of insulin treatment on muscle mass and strength are unknown. In this study, we revealed that insulin treatment significantly attenuated the decline of skeletal muscle mass in patients with type 2 diabetes. This association remained when we used PS matching.

The protective effect of insulin on the reduction of muscle mass was primarily observed in the lower extremities (Table 3; Fig. 2). Although the protective mechanism of insulin on the progression of muscle dysfunction that was dominant in the lower extremities remains unclear, some previous reports provide important speculation [21, 22]. Patients with diabetes, especially those with a longer duration of the disease are at an increased risk for poor muscle strength in the quadriceps [21] and walking impairments [22]. These data suggest the possibility that patients with a long duration of diabetes are more likely to develop muscle dysfunction in the lower extremities rather than in the upper extremities. Compared with the diabetic patients who have had the disease for a short duration, those with a long duration exhibit low endogenous insulin levels in the bloodstream, implying that insulin signaling in the skeletal muscle may be impaired. This results in low muscle mass and decreased function in diabetic patients with a long duration of diabetes. Thus, it is possible that an efficient supply of exogenous insulin could improve insulin signaling in the skeletal muscle, promote protein synthesis, and protect against the loss of muscle mass among patients with diabetes, especially those with a long duration of diabetes. In addition, we used a multivariate model to identify the 1-year changes in the HbA1c and BMI levels as covariates that insulin treatment remained to significantly increase muscle mass. These findings provide evidence that the protective effects of insulin treatment on the decline of muscle mass may be independent of an improvement in glycemic control or load increase. Therefore, the resolution of the relative insufficiency of insulin via exogenous insulin injections may be the main factor with regards to the protection of muscle mass in this study. We further determined whether the change in SMI in patients with insulin treatment was correlated with that in body fat and cardiometabolic risk factors. We found that the change in SMI was indeed correlated with the change in HbA1c, HDL cholesterol, and uric acid. These data suggest that the increase in muscle mass induced by insulin treatment may reflect an improvement in peripheral insulin resistance. Based on our findings and the results from previous studies [21, 22], insulin treatment could be plausible means of preserving muscle function while also improving the glycemic control of patients with diabetes who are affected by low muscle mass and strength in the lower extremities.

Combined with the potential of insulin treatment to preserve muscle function and mass, it should be emphasized that insulin treatment should be initiated with the careful consideration of adverse effects, particularly hypoglycemia. Hypoglycemia increases the risk of dementia, falls, cardiovascular events and mortality in elderly patients with diabetes [23]. In particular, falls are the major cause of injury and a significant source of morbidity and disability which can severely reduce the QOL among the elderly. Comorbidities (e.g., chronic kidney disease) further increase the risk for hypoglycemia in elderly patients with diabetes. In addition, insulin treatment has the potential to increase body fat. The accumulation of body fat, particularly abdominal visceral fat, has been recognized as a strong contributor to the development of CVD and metabolic disorders, including diabetes [24, 25]. Therefore, physicians should balance the potential benefits and risks when recommending the use of insulin.
In addition to insulin treatment, the durations of diabetes and BMI were found to be significant predictors for the changes in SMI in this study (Table 3). Moreover, the presence of diabetes, poor glycemic control, and insulin resistance have been reported to increase the risk for lowering muscle mass and function in elderly individuals [5, 7, 8, 13, 26]. Therefore, it is conceivable that patients with a long duration of diabetes may be exposed to hyperglycemia and insulin resistance much longer than those with a short duration of diabetes, resulting in a reduction of muscle mass and function. In contrast, the negative association of the BMI with a change in SMI seems odd since patients with a high BMI are subjected to a high load (high body weight) and may be protective against the loss of muscle mass and function. One potential explanation is that patients with a high BMI are more likely to be obese and those who lost more weight (fat and non-fat mass) than non-obese patients via calorie restriction during the follow-up period, would exhibit a reduction in the SMI; however, no information regarding diet was available in this study.

This study has several limitations: (1) generalization of the findings of this study is limited due to the study design (hospital-based study including only Japanese individuals with type 2 diabetes); (2) propensity scores do not eliminate bias if there are unmeasured confounders; (3) information regarding changes in grip strength was not available and the follow-up period for muscle mass was relatively short; (4) we were unable to obtain data regarding diet and exercise, or diabetic neuropathy, all of which may affect muscle function; (5) we measured the grip strength in both the dominant and non-dominant hands once and used the average values to assess the degree of muscle strength in this study. Recently, a standardized protocol for grip strength measurements was suggested by Roberts HC et al. to improve the assessment of sarcopenia [27]. The protocol proposes that three measurements of grip strength should be conducted for each hand, and the maximal grip score obtained from all six trials should be used as the grip strength in the statistical analysis. Therefore, we should have measured a grip strength in accordance with this protocol; and (6) there was a significant difference in the age between the patients treated with insulin and those who were not. Sarcopenia occurs with advancing age (aging is the strongest contributor to the progression of sarcopenia); therefore, age differences could influence the outcome data, particularly regarding the effect of insulin treatment on muscle mass; however, insulin treatment was significantly associated with preserved muscle mass even after adjusting for covariates, including aging. Furthermore, it should be considered that the older age of patients receiving insulin treatment may underestimate but not overestimate the favorable effects of insulin treatment on muscle mass.

In summary, our data suggest that patients with type 2 diabetes treated with insulin may be at a lower risk for the loss of skeletal muscle mass in the lower extremities, compared with those who do not receive insulin treatment. Whether the administration of insulin influences the incident sarcopenia in randomized controlled trials remains to be elucidated.

Funding This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Author Contributors Author RB designed the study and prepared the first draft of the paper. He is guarantor. RB, TF, IM, TY, and YO contributed to intellectual discussion and reviewed and edited the manuscript. TT, MM, HI, and KH researched data. All authors revised the paper critically for intellectual content and approved the final version. All authors agree to be accountable for the work and to ensure that any questions relating to the accuracy and integrity of the paper are investigated and properly resolved.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

Human and Animal Rights The study was conducted in accordance with the ethics principles of the Declaration of Helsinki and was approved by the ethics committee of Tokyo Medical and Dental University.

Informed Consent Informed consent was not obtained from the patients because this study is a observational analysis.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. European Working Group on Sarcopenia in Older People (2010) European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing 39:412–423. doi:10.1093/ageing/afq034
2. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kantan A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences.
1. Chen CK, Liu Y, Li S, Assantachai P, Auyeung TW, Bahy Y, Chen YH, Chen LY, Hu Y, Krairitch O, Lee J, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15:95–101. doi:10.1016/j.jamda.2013.11.025
2. Cruz-Jentoft AJ, Michel JP (2013) Sarcopenia: A useful paradigm for physical frailty. Eur Geriatr Med 4:102–105. doi:10.1016/j.eurger.2013.02.009
3. Kalyani RR, Corriere M, Ferrucci L (2014) Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2:819–829. doi:10.1016/S2213-8587(14)70034-8
4. Park SW, Goodpaster BH, Strotmeyer ES, de Rekenere N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB (2006) Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 55:1813–1818. doi:10.2337/db05-1183
5. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekenere N, Harris TB, Schwartz AV, Tylavsky FA, Cho YW, Newman AB; Health, Aging, and Body Composition Study (2007) Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the ‘Darwin study’. Diabetes Care 30:1507–1512. doi:10.2337/dc06-2537
6. Park SW, Goodpaster BH, Lee JS, Kuller LH, Broudeau R, de Rekenere N, Harris TB, Krilevich S, Tylavsky FA, Nevitt M, Cho YW, Newman AB; Health, Aging, and Body Composition Study (2009) Health, Aging, and Body Composition Study. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 32:1993–1997. doi:10.2337/dc09-0264
7. Wakahayashi H, Sakuma K (2014) Comprehensive approach to sarcopenia treatment. Curr Clin Pharmacol 9:171–180. doi:10.2174/157488481066613111192845
8. Cermak NM, Reep PT, de Groot LC, Saris WH, van Loon LJ (2012) Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr 96:1454–1464. doi:10.3945/ajcn.112.037556
9. Laas O, Alonso C, Castro M, Rodriguez-Manas L (2014) Pharmacological interventions for frailty and sarcopenia. Curr Pharm Des 20:3068–3082. doi:10.2174/13816128113196660705
10. Mavros Y, Kay S, Anderberg KA, Baker MK, Wang Y, Zhao R, Meiklejohn J, Cimlisteen M, O’Sullivan A, de Vos N, Baune BT, Blair SN, Simar D, Rooney K, Singh N, Fiatarone Singh MA (2013) Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in older adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. Diabetes Care 36:2372–2379. doi:10.2337/dc12-2196
11. Kalyani RR, Mrager ET, Egan J, Golden SH, Ferrucci L (2015) Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care 38:82–90. doi:10.2337/dc14-1166
12. Lee CG, Boyko EJ, Barrett-Conner E, Miljkovic I, Hoffman AR, Everson-Rose SA, Lewis CE, Cawthon PM, Strotmeyer ES, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Study Research Group (2011) Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 34:2381–2386. doi:10.2337/dc11-1032
13. Tanaka Kanazawa I, Sugimoto T (2015) Reduction in endogenous insulin secretion is a risk factor of sarcopenia in men with type 2 diabetes mellitus. Caecif Tissue Int 97:385–390. doi:10.1007/s00223-015-0990-8
14. Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E (2009) Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia 52:1889–1898. doi:10.1007/s00125-009-1430-8
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamakaga T, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992. doi:10.1053/j.ajkd.2008.12.034
16. Menink M, Hesselink MK, Russell AP, Schaal G, Sels JP, Schrauwen P (2007) Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond) 31:1302–1310. doi:10.1038/sj.ijo.0803567
17. Sällé A, Guilleoteau G, Ryan M, Bouhanick B, Ritz P (2004) Effect of insulin treatment on the body composition of Type 2 diabetic patients. Diabet Med 21:1298–1303. doi:10.1111/j.1464-5491.2004.01335.x
18. Packmanathan IC, Fuller NJ, Peterson DB, Wright WA, Finer N (2005) Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the ‘Darwin study’. Diabetologia 48:222–229. doi:10.1007/s00125-004-1642-x
19. Kalyani RR, Tra Y, Yeh HC, Egan JM, Ferrucci L, Brancati FL (2013) Quadriceps strength, quadriceps power, and gait speed in older U.S. adults with diabetes mellitus: results from the National Health and Nutrition Examination Survey, 1999–2002. J Am Geriatr Soc 61:769–775. doi:10.1111/j.1532-5417.2012.14204.x
20. Wolpato S, Bianchi L, Laurentana F, Laurentana F, Bandinelli S, Guralnik JM, Zuliani G, Ferrucci L (2012) Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care 35:1672–1679. doi:10.2337/dc11-2202
21. Skyler JS, Bergensal R, Bobov RO, Buse J, Deedwania P, Gale EA, Howard BK, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187–192. doi:10.2337/dc08-0026
22. Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Vranenburg J, Nilwik R, van Loon Lj (2013) Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 14:585–592. doi:10.1016/j.jamda.2013.02.006
23. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D’Argostino RB Sr, O’Donnell CJ (2007) Abbdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39–48. doi:10.1161/CIRCULATIONAHA.106.675355
24. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS (2013) Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 62:921–925. doi:10.1016/j.jacc.2013.06.027
25. Roberts HC, Denison HH, Martin HH, Patel HP, Syddall H, Cooper C, Sayer AA (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40:423–429. doi:10.1093/ageing/afr051

Springer